8-K: Tharimmune Secures $2.5 Million in Private Placement to Fuel Clinical Development and Operations

Tharimmune, Inc. has entered into a private placement agreement to raise approximately $2.5 million through the issuance of common stock and various warrants, earmarked for clinical development and working capital.

Summary

• Tharimmune, Inc. (the "Company") entered into a Securities Purchase Agreement on June 13, 2025, with certain accredited investors for a private placement.
• The private placement is expected to close on June 20, 2025, and is anticipated to generate approximately $2.5 million in gross proceeds for the Company.
• The offering includes the issuance and sale of 1,551,351 shares of the Company's common stock.
• Additionally, the Company will issue pre-funded warrants to purchase up to 137,838 shares of common stock at a nominal exercise price of $0.001 per share, exercisable immediately.
• Series A warrants to purchase up to 1,689,189 shares of common stock will be issued with an exercise price of $1.29 per share, exercisable six months from issuance and valid for five and a half years.
• Series B warrants to purchase up to 844,572 shares of common stock will be issued with an exercise price of $3.00 per share, also exercisable six months from issuance and valid for five and a half years.
• The net proceeds from this private placement are intended for clinical development and general working capital purposes.
• President Street Global served as the exclusive placement agent for this transaction, receiving fees and expenses.
• A beneficial ownership limitation prevents holders from exercising warrants if it would result in them owning more than 4.99% (or 9.99% at the holder's election) of the Company's outstanding common stock immediately after exercise.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for Tharimmune's clinical development and operations, which is a positive and essential step for a biotech company. However, the significant potential for future dilution from the warrants and the disclosed conflict of interest warrant a cautious approach, preventing a higher sentiment score.

Positives

• The private placement secures approximately $2.5 million in gross proceeds, providing essential capital for Tharimmune's clinical development programs and general working capital.
• The inclusion of pre-funded warrants with a nominal exercise price ($0.001) allows investors to acquire shares immediately while providing upfront capital to the Company.
• The Company has committed to filing a Form S-3 registration statement within 30 days post-closing and using commercially reasonable efforts to make it effective within 60 days, which facilitates liquidity for investors.
• The Company covenants to maintain its listing on The Nasdaq Stock Market LLC, ensuring continued market access for its shares.

Negatives

• The issuance of common stock alongside three types of warrants (pre-funded, Series A, and Series B) introduces significant potential for future dilution to existing shareholders upon warrant exercise.
• The exercise prices of the Series A ($1.29) and Series B ($3.00) warrants, while tiered, may be perceived as low relative to the Company's potential future valuation, potentially indicating a discount to market or a low current valuation.
• Placement agent fees and other offering expenses will reduce the net proceeds received by the Company from the $2.5 million gross amount.
• A potential conflict of interest exists as an indirect owner of the placement agent is also an investment manager at the Company's largest shareholder, who may indirectly benefit from the transaction's compensation.

Risks

• Significant future dilution of common stock from the exercise of pre-funded, Series A, and Series B warrants.
• The Company's failure to timely deliver warrant shares upon exercise could result in liquidated damages or require the Company to compensate holders for 'Buy-In' costs.
• The securities acquired in this private placement are restricted and subject to resale limitations under state and federal securities laws, unless registered or eligible for Rule 144.
• The Company must maintain its listing on The Nasdaq Stock Market LLC; failure to comply with listing requirements could lead to delisting.
• The Company must ensure it conducts its business in a manner that avoids becoming an investment company subject to registration under the Investment Company Act of 1940.
• The Company has a disclosed Delaware franchise tax delinquency, which could pose a minor compliance risk.

Future Outlook

Tharimmune intends to utilize the net proceeds from this private placement primarily for clinical development and general working capital, signaling a commitment to advancing its pipeline and supporting ongoing operations. The Company also plans to file a registration statement to facilitate the resale of the newly issued securities, ensuring future liquidity for investors.

Industry Context

This private placement is a common financing mechanism for small-cap biotechnology or pharmaceutical companies like Tharimmune, which typically rely on equity capital to fund their research, development, and clinical trial activities, given their often limited or non-existent revenue streams. The issuance of common stock alongside various tranches of warrants is a standard practice to attract investors by offering additional upside potential and flexibility, while also managing immediate cash needs and beneficial ownership limitations. The terms, including tiered exercise prices and participation rights in future financings, are typical investor protections in such deals.

Comparison to Industry Standards

• The use of a private placement with a combination of common stock and warrants (pre-funded, Series A, Series B) is a widely accepted and common financing structure for early to mid-stage biotech companies seeking capital for clinical development, similar to financings seen with companies like 'X Biotech' or 'Y Pharma' at comparable stages.
• The beneficial ownership limitation of 4.99% (or 9.99% at holder's election) is a standard provision in private placements to prevent investors from triggering certain SEC reporting requirements (e.g., Schedule 13D) or corporate anti-takeover provisions, aligning with market norms.
• The inclusion of pre-funded warrants with a nominal exercise price is a common strategy to allow investors to acquire shares immediately while managing their beneficial ownership percentages and providing upfront capital to the company, a mechanism frequently observed in similar transactions.
• The commitment to file a Form S-3 registration statement within 30 days and achieve effectiveness within 60 days is a standard liquidity provision for investors in private placements, comparable to terms offered by other publicly traded development-stage companies.
• The 'participation right' in future equity financings (Section 4.13) provides anti-dilution protection to the current investors, a common feature in private investment in public equity (PIPE) transactions to maintain pro-rata ownership.
• The disclosed potential conflict of interest involving the placement agent and a major shareholder, while requiring transparency, is not an anomaly in the smaller end of the capital markets where relationships can be more intertwined, though it warrants careful scrutiny by investors.

Corporate Governance

Related Party Transactions

• Vincent LoPriore, an investment manager at Gravitas Capital LP (identified as the largest shareholder of the Company), is also an indirect owner of the holding company of President Street Global, LLC.
• President Street Global, LLC served as the Company's exclusive placement agent for this private placement and is receiving a monthly retainer and a success fee.
• Mr. LoPriore may indirectly benefit from the compensation paid to President Street Global, LLC, which is noted as a potential conflict of interest.

Stakeholder Impact

• Shareholders: Face potential significant dilution from the exercise of the various warrants issued in this private placement. However, the capital raise provides necessary funding for the Company's operations and clinical development, which could support long-term value if successful.
• Investors (Purchasers in Private Placement): Acquire common stock and warrants, offering potential upside if the stock price appreciates. They also benefit from anti-dilution provisions like participation rights in future financings and specific remedies for the Company's non-compliance.
• Employees: The capital infusion supports the Company's continued operations and clinical development, potentially securing jobs and future growth opportunities.
• Creditors: The additional capital strengthens the Company's financial position, potentially reducing short-term liquidity risks and improving its ability to meet obligations.

Next Steps

• The closing of the private placement is expected to occur on June 20, 2025.
• The Company will file a Current Report on Form 8-K, including the Transaction Documents as exhibits, within the time required by the Exchange Act.
• The Company is obligated to file a registration statement on Form S-3 (or other appropriate form) within 30 days following the Closing Date to allow for the resale of the Securities by the Purchasers.
• The Company will use commercially reasonable efforts to cause the registration statement to become effective within 60 days following its filing.
• The Company will use the net proceeds from the private placement for clinical development and working capital.
• The Company agrees to maintain the listing or quotation of its Common Stock on The Nasdaq Stock Market LLC.

Key Dates

Recommendation

Keywords

Tharimmune, Private Placement, Warrants, Common Stock, Capital Raise, Clinical Development, Working Capital, SEC Filing, Form 8-K, Equity Financing, Dilution, Nasdaq, Biotechnology, Pharmaceutical